<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841776</url>
  </required_header>
  <id_info>
    <org_study_id>DTG0703</org_study_id>
    <nct_id>NCT00841776</nct_id>
  </id_info>
  <brief_title>Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne</brief_title>
  <official_title>Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Moderate to Moderately Severe Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the development of microbial resistance when using
      one of two topical acne therapies for the treatment of  facial acne vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the development of microbial resistance when using one of two topical acne
      therapies for the treatment of moderate to moderately severe facial acne vulgaris. Clinical
      efficacy and tolerability will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Median Change in Total Propionibacterium Acne (P.Acne) Counts</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, &amp; 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median change in total colony forming units of propionibacterium acne (P.acne) will be counted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Change in Clindamycin Resistant P. Acne.</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median change in total colony forming units of clindamycin resistant p. acne.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Erythromycin-resistant P. Acne Counts</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total colony forming units of erythromycin-resistant p. acnes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Total Acne Lesions</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median Change in Total Acne Lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median Change in Inflammatory Acne Lesion Counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Noninflammaotry Acne Counts</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median Change in Noninflammaotry Acne Counts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Duac gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin and benzoyl peroxide gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ziana gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin and tretinoin gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duac</intervention_name>
    <description>Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks</description>
    <arm_group_label>Duac gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziana gel</intervention_name>
    <description>Clindamycin and tretinoin gel once a day for 12 weeks.</description>
    <arm_group_label>Ziana gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient at least 12 years of age. Female subjects of childbearing potential must
             have a negative urine pregnancy test result at baseline and practice a reliable
             method of contraception throughout the study.

          -  Mild to moderate facial acne vulgaris

          -  Able to understand the requirements of the study and sign informed consent/HIPAA
             authorization forms. Subjects under the legal age of consent in the state where the
             study is conducted must also have the written, informed consent of a parent or legal
             guardian.

        Exclusion Criteria:

          -  Female subjects who are pregnant (positive urine pregnancy test), breast feeding or
             who are of childbearing potential and not practicing a reliable method of birth
             control

          -  Allergy or sensitivity to any component of the test medication

          -  Known hypersensitivity to to any component of the investigational formulations

          -  Known history of enteritis (regional enteritis, ulcerative colitis, pseudomembranous
             colitis, or antibiotic-associated colitis

          -  Beards or sideburns

          -  Skin disease/disorder that might interfere with the diagnosis or evaluation of acne
             vulgaris

          -  Evidence of recent alcohol or drug abuse

          -  Participation in an investigational drug study within 30 days of the baseline visit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Specialists, PSC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin We Care Dermatology</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jackson JM, Fu JJ, Almekinder JL. A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/ clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. J Drugs Dermatol. 2010 Feb;9(2):131-6.</citation>
    <PMID>20214175</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 12, 2011</lastchanged_date>
  <firstreceived_date>February 10, 2009</firstreceived_date>
  <firstreceived_results_date>April 7, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri A. Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Acne</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
